Startups
Veeva Systems is a leader in cloud-based software for the global life sciences industry. Our customers achieve the fastest time to value through the deployment of fully functional business applications that are flexible to change, simple to deploy, inexpensive to operate, and provide a superior user experience.
Overview
Location
United States, Washington, Seattle
Employees
51-200
Phone
(925) 452-6500
Total raised
$183.5M
Founded date
2008
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Vivo Capital | vivocapital.com | |
| Kohlberg Kravis Roberts | kkr.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Dec 6, 2018 | Series D round | $67.5M | |
| Dec 6, 2016 | Series C round | $36M |
Mentions in press and media 26
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 18, 2022 | Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights | Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable Trudhesa™ Payer Coverage with Signed Agree... |
| Jan 18, 2022 | Impel NeuroPharma : Provides Updates on TrudhesaTM Launch and Recent Business Highlights - Form 8-K | Impel NeuroPharma Provides Updates on TrudhesaTM Launch and Recent Business Highlights Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company&#... |
| Nov 15, 2021 | Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update | Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adults Mobilized 60-Person Salesforce with a Targeted Focus on High-Prescribing Neurologists, Head... |
| Nov 15, 2021 | Impel NeuroPharma : Announces THIRD Quarter 2021 Financial Results and Provides CORPORATE Update - Form 8-K | Impel NeuroPharma Announces THIRD Quarter 2021 Financial Results and Provides CORPORATE Update Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adu... |
| Sep 29, 2021 | Impel NeuroPharma : Announces Trudhesa (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine | SEATTLE - Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervou... |
| Sep 28, 2021 | Impel NeuroPharma : Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine | Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space Trudhesa is Available Through Trudhesa Direct™, Whic... |
| Sep 10, 2021 | Impel NeuroPharma : Announces Pricing of $45.0 Million Public Offering | SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an i... |
| Aug 16, 2021 | Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update | TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021 Preparations On Track for Potential TRUDHESA Launch in the Fourth Quarter of 2021 Increased Ca... |
| Aug 16, 2021 | Impel NeuroPharma : Increased Cash Position and Extended Runway through 2022 Following $50 Million Debt Facility Agreement with Oxford Finance LLC and Silicon Valley Bank (Form 8-K) | Increased Cash Position and Extended Runway through 2022 Following $50 Million Debt Facility Agreement with Oxford Finance LLC and Silicon Valley Bank Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, August 16, 2021 - I... |
Show more
Reviews 0
FAQ about Impel NeuroPharma
When was Impel NeuroPharma founded?
Impel NeuroPharma was founded in 2008.
How much funding has Impel NeuroPharma raised?
Impel NeuroPharma has raised $183.5M in total across 3 funding rounds.
What funding rounds has Impel NeuroPharma raised?
Parsers VC lists 3 funding rounds of Impel NeuroPharma, among them a Series D round of $67.5M on Dec 6, 2018 and a Series C round of $36M on Dec 6, 2016.
Who has invested in Impel NeuroPharma?
Parsers VC lists 3 investors of Impel NeuroPharma, among them Vivo Capital and Kohlberg Kravis Roberts.
What has the press written about Impel NeuroPharma?
Parsers VC has collected 26 articles mentioning Impel NeuroPharma, among them “Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights” (Jan 18, 2022) and “Impel NeuroPharma : Provides Updates on TrudhesaTM Launch and Recent Business Highlights - Form 8-K” (Jan 18, 2022).
Is Impel NeuroPharma still active?
Yes, Impel NeuroPharma is active; its latest activity on Parsers VC dates from Jan 19, 2022.